Blog

One of the sources confirmed the deal would be worth around $4 billion, as per an earlier report by the Wall Street Journal, which was first to report the development.

Sign up here.

L’Oreal, the world’s biggest dedicated cosmetics and beauty player, would acquire fragrance brand Creed and gain rights to develop beauty products tied to Kering’s fashion labels, including Bottega Veneta, Balenciaga, and McQueen, the WSJ reported, adding the deal could be announced next week.

Kering, controlled by the French Pinault family, launched its beauty division in 2023, the year it acquired high-end fragrance label Creed for 3.5 billion euros ($4 billion) in cash.

Kering declined to comment and L’Oreal did not immediately respond to a Reuters request for comment.

A sale would be a major step forward by new CEO Luca De Meo, who officially took office in September, to address a high-debt issue that had sparked investor anxiety.

Kering’s net debt was 9.5 billion euros at the end of June.

The company has struggled to reverse slowing sales at its largest brand Gucci as the luxury market has been hard hit by lower consumer demand, especially in China, which had led growth in the sector for more than a decade.

Since Kering announced De Meo’s appointment in mid-June, shares in the company have surged by around 60%.

($1 = 0.8583 euros)

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below.

In his early days as a real estate investor, Mike Zuber started to establish a set of criteria for the types of properties he’d consider buying. Among other things, he wanted single-family homes, with three to four bedrooms, in specific zip codes in Fresno, California. By sticking to that list, he told Business Insider, he was able to scale to more than 100 cash-flowing units, which allowed both him and his wife to quit their full-time jobs.

This strategy, known as the “buy box” strategy, has allowed many new investors to gain a foothold in the industry and grow their portfolios.

Don’t Miss:

“Most new investors are all over the map,” Zuber told BI. “The first step any new investor needs to do is focus. If you’re going to be a buy-and-hold investor in a new area, get a buy box and make it hyper-focused.”

There are several steps experts suggest taking when beginning to define your buy box. The first is to drive through various neighborhoods, attend open houses, and look at as many existing rental properties as you can. This will allow you to get a feel for the area, as well as the demand and type of resident you’re likely to attract.

Next, they suggest doing your research. Looking into the area’s plans for infrastructure, employment growth, and community growth can help determine the potential future value of your home, they told BI. So spending a few hours digging up a city or county’s 10-year strategic growth plan is well worth your time.

Trending: This Jeff Bezos-backed startup will allow you to become a landlord in just 10 minutes, with minimum investments as low as $100.

“Being a bit more rigorous about it can really pay dividends,” Grant Sabatier, a financially independent real estate investor with properties in New York City, told BI. “That’s what I did: I was laser focused on a five-block by four-block radius for a six-month period and then knew immediately when there was a deal that was perfect based on my criteria.”

“The more you know your buy box, the better your chances are at finding a great deal,” Zuber told BI. “You can’t be casual. It has to be purposeful and intentional.”

For Zuber, a great deal is one that has high cash-on-return, or the annual return he makes on a property in relation to how much he spends on that property over the course of a year.

Atai Life Sciences (NasdaqGM:ATAI) and its partner Beckley Psytech just received Breakthrough Therapy designation from the FDA for BPL-003, their investigational nasal spray for treatment-resistant depression. This recognition accelerates the path to potential approval and highlights excitement about new mental health therapies.

See our latest analysis for Atai Life Sciences.

Atai’s FDA breakthrough news supercharged momentum that was already building. The share price has spiked 303% year-to-date, and the 1-year total shareholder return is an eye-popping 404%. With fresh capital raised through a $130 million equity offering and continued sector-wide interest in psychedelic medicines, investors are clearly betting on both near-term catalysts and the company’s longer-term potential.

If regulatory milestones like this have you curious about other breakthrough opportunities, this is a great time to explore the latest See the full list for free..

With Atai’s massive rally, strong analyst buy ratings, and a price target well above current levels, investors are now asking whether the stock remains undervalued or if recent gains have already priced in the next stage of growth.

Atai Life Sciences trades at a price-to-book ratio of 9.6x, placing it well above the typical level in the pharmaceutical industry and raising questions about how much growth is being priced in at $6.45 per share.

The price-to-book ratio compares a company’s market value to its book value, providing a sense of how much investors are willing to pay for each dollar of assets. In pharmaceuticals, where early-stage R&D companies are often years from profitability, elevated price-to-book multiples can reflect either strong future expectations or indicate market exuberance.

While Atai’s ratio trails the peer group average of 11.3x, it remains much higher than the broader US Pharmaceuticals industry average of 2.4x. This suggests investors have high expectations, but maintaining this premium may be challenging without substantial revenue growth or positive earnings developments to support this year’s performance.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-Book of 9.6x (OVERVALUED)

However, weak profitability and the potential for slower revenue growth could quickly cool investor enthusiasm if expectations get ahead of fundamentals.

Find out about the key risks to this Atai Life Sciences narrative.

If you have your own perspective or want to dive deeper, you can examine the numbers and construct your own take in just a few minutes, or Do it your way.

A great starting point for your Atai Life Sciences research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.

Now is the perfect moment to broaden your perspective and act on investment opportunities beyond Atai Life Sciences. You could miss tomorrow’s biggest winner if you only look in one place.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ATAI.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com